Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Epidermal growth factor receptor (EGFR) mutation is a reliable and sensitive biomarker for EGFR-TKI therapy in non-small-cell lung cancer (NSCLC). However, detection of EGFR mutation in tissues has obvious limitations. Circulating free DNA (cfDNA) has been reported as an alternative approach for the detection of EGFR mutations. This systematic review and meta-analysis was designed to assess the diagnostic performance of cfDNA, compared with tissues. True-positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN) values were extracted or calculated for each study. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were calculated. A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall diagnostic performance. 20 eligible studies involving 2012 cases were included in this meta-analysis. The pooled sensitivity, specificity, PLR, NLR, and DOR were 0.674 (95%CI: 0.517-0.800), 0.935 (95%CI: 0.888-0.963), 10.307 (95%CI: 6.167-17.227), 0.348 (95%CI: 0.226-0.537), and 29.582 (95%CI: 4.582-60.012), respectively. The AUC was 0.93 (95% CI: 0.90-0.95). The meta-analysis suggests that detection of EGFR mutation by cfDNA is of adequate diagnostic accuracy and cfDNA analysis could be a promising screening test for NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EGFR mutations detected in plasma and urine have been shown to be concordant with those identified by tumor biopsy”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“Noninvasive genotyping of cell-free plasma DNA (cfDNA) represents an attractive alternative for detection of EGFR T790M, noting that plasma genotyping for EGFR-sensitizing mutations is an established alternative in Europe when tumor genotyping is not feasible.19”
From Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer (2016) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Deeks, J. J., Macaskill, P., & Irwig, L. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.01.016 · Cited by 2,910
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The diagnostic odds ratio: a single indicator of test performance
Glas, A. S., Lijmer, J. G., Prins, M. H., Bonsel, G. J., & Bossuyt, P. M. M. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(03)00177-x · Cited by 2,261
Cited by
Items 101–200 of 212
Circulating Tumor DNA in Non–Small-Cell Lung Cancer: A Primer for the Clinician
Singh, A. P., Cheng, H., Guo, X., Levy, B. P., & Halmos, B. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00054 · Cited by 24
EGFR inhibition in NSCLC: New findings…. and opened questions?
Passiglia, F., Listì, A., Castiglia, M., Perez, A., Rizzo, S., Bazan, V., & Russo, A. D. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.009 · Cited by 22
Saad, N., Poudel, A., Basnet, A., & Gajra, A. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s100650 · Cited by 24
Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer
Pešta, M., Shetti, D., Kulda, V., Knížková, T., Houfková, K., Bagheri, M. S., Svatoň, M., & Polívka, J. (2022) · Diagnostics · doi:10.3390/diagnostics12081799 · Cited by 23
Zhu, Y.-J., Zhang, H.-B., Liu, Y., Zhang, F., Zhu, Y., Li, Y., Bai, J., Liu, L., Qu, Y., Qu, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14490 · Cited by 21
Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications
Huang, C.-L., Liu, S., Tong, X., & Fan, H. S. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3586-8 · Cited by 23
Kim, Y., Shin, S., & Lee, K. (2018) · BioMed Research International · doi:10.1155/2018/7392419 · Cited by 26
“T790M, from cfDNA in non-small cell lung cancer (NSCLC) patients, although the sensitivities and specificities of the methods vary [4, 5].”
BackgroundFernandes, G., Sousa, C., Reis, J. P., Martins, N. A., Moura, C. S., Guimarães, S., Justino, A., Pina, M. J., Magalhães, A., Queiroga, H., et al. (2021) · Cells · doi:10.3390/cells10081912 · Cited by 22
“Previous studies have proven the feasibility of detecting EGFR mutations in ctDNA [4,5], while predictive markers of response to EGFR tyrosine kinase therapy [10,11] can be used for monitoring EGFR alterations in plasma during the disease [6,12,13].”
BackgroundMethodHaselmann, V., Hedtke, M., & Neumaier, M. (2022) · Diagnostics · doi:10.3390/diagnostics12030748 · Cited by 22
Savaş, İ. N., & Coşkun, A. (2025) · Biomolecules · doi:10.3390/biom15071011 · Cited by 28
“Examples of mutations detected via cfDNA are EGFR and KRAS , which are clinically important for the management of lung cancer [153,154], and mutations in TERT and TP53 , which have broader applicability across various cancer types [118] (Figure 1B).”
Zhang, Y., Zheng, H., Zhan, Y., Long, M., Liu, S., Lu, J., Zang, H., & Fan, S. (2018) · Europe PMC (PubMed Central) · Cited by 19
Fernandes, G., Martins, N. A., Moura, C. S., Guimarães, S., Reis, J. P., Justino, A., Pina, M. J., Magalhães, A., Queiroga, H., Machado, J. C., et al. (2021) · Cancers · doi:10.3390/cancers13112707 · Cited by 19
“The applicability of liquid biopsy to LC began with the analysis of EGFR mutational status on circulating cell-free DNA, as was documented in several studies [25,26] and meta-analysis [27,28].”
BackgroundPandey, A., Dutt, S., Singh, A., Kumar, A., & Singh, S. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_60_19 · Cited by 18
“[32] Peripheral blood ctDNA has also emerged as an alternate diagnostic tool, which has been prospectively validated with matched tumor tissue‐based EGFR molecular testing with excellent concordance and diagnostic accuracy in a prospective study and meta‐analysis when performed at baseline.[12,13] Despite this, no stu…”
ResultClinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review
Nigro, M. C., Marchese, P. V., Deiana, C., Casadio, C., Galvani, L., Federico, A. D., & Giglio, A. D. (2023) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s388047 · Cited by 25
Siggillino, A., Ulivi, P., Pasini, L., Reda, M. S., Chiadini, E., Tofanetti, F. R., Baglivo, S., Metro, G., Crinò, L., Delmonte, A., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10121062 · Cited by 18
Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy
Ruysscher, D. D., Jin, J., Lautenschlaeger, T., She, J., Liao, Z. X., & Kong, F. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.09.12 · Cited by 17
“ctDNA analysis has become an established alternative to determine EGFR status (50).”
Backgroundvan der Leest, P., Janning, M., Rifaela, N., Azpurua, M. L. A., Kropidlowski, J., Loges, S., Lozano, N., Sartori, A., Irwin, D. L., Lamy, P., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713390 · Cited by 17
“The analytical sensitivity to detect EGFR mutations in the cell-free plasma of NSCLC patients with methods such as Cobas® [38], ddPCR [9], and ARMS [39] revealed a pooled sensitivity of 67% and a specificity of 94% [40].”
Methodwritten on behalf of AME Lung Cancer Collaborative Group, Xu, H., Baidoo, A. A. H., Su, S., Ye, J., Chen, C., Xie, Y., Bertolaccini, L., Ismail, M., Ricciuti, B., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.03.10 · Cited by 15
“5–100% specificity when testing plasma when compared with the matched tumor tissues for the EGFR mutation status (8,18,28,30,31).”
MethodLi, J., Li, X., Wang, W., Shao, Y. W., Zhang, Y., & Song, Z. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100784 · Cited by 16
“tumor tissue, with a sensitivity ranging from 70% to 80% [16,17].”
BackgroundFernandes, M. G. O., Martins, N. A., Machado, J. C., Costa, J. L., & Hespanhol, V. P. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02382-0 · Cited by 18
A liquid biopsy in primary lung cancer
Yoneda, K., Imanishi, N., Ichiki, Y., & Tanaka, F. (2018) · Surgery Today · doi:10.1007/s00595-018-1659-2 · Cited by 17
“4%) may be a critical issue when deciding on systemic treatment [33], as EGFR-mutated patients with “false-negative” results (EGFR-mutation, not detected in the plasma) may not be treated with the optimum agent (EGFR-TKI).”
BackgroundCell-Free DNA Diagnostics: Current and Emerging Applications in Oncology
Muluhngwi, P., Valdes, R., Fernandez-Botrán, R., Burton, E., Williams, B. J., & Linder, M. W. (2019) · Pharmacogenomics · doi:10.2217/pgs-2018-0174 · Cited by 17
Malapelle, U., Pilotto, S., Passiglia, F., Pepe, F., Pisapia, P., Righi, L., Listì, A., Bironzo, P., Belluomini, L., Tabbò, F., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103300 · Cited by 19
Zhu, L., Zhang, S., Xun, Y., Jiang, Y., Xia, B., Chen, X., Wang, L., Jiang, H., & Ma, S. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0286-3 · Cited by 16
“This method can detect mutations in samples containing as little as 1% mutated DNA [31–34] and achieves moderate sensitivity but high specificity when using plasma ctDNA to detect EGFR mutations [35, 36].”
MethodWulandari, L., Soegiarto, G., Febriani, A., Wati, F. F., & Sahrun (2020) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-020-01046-1 · Cited by 17
Circulating tumor DNA in endometrial cancer: clinical significance and implications
Capasso, I., Nero, C., Anderson, G., Re, M. D., Perrone, E., Fanfani, F., Scambia, G., Cucinella, G., Mariani, A., Choong, G. M. Y., et al. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.101656 · Cited by 17
The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer
Huang, W.-L., Wei, F., Wong, D. T., Lin, C., & Su, W. (2015) · BioMed Research International · doi:10.1155/2015/340732 · Cited by 14
“Concerning the comparison of the sensitivity of these methods, recently a meta-analysis study demonstrated that DHPLC and HRM showed higher sensitivity than ARMS in subgroup analyses [81].”
ResultTao, S., Ju, X., Zhou, H., & Zeng, Q. (2020) · The International Journal of Biological Markers · doi:10.1177/1724600820967124 · Cited by 15
Wang, H.-Y., Liao, W., Ho, C., Wu, S., Yang, C., Hsu, C., Lin, Y., Yang, J. C., & Shih, J.-Y. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115224 · Cited by 16
The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era
Costa, J., Membrino, A., Zanchetta, C., Rizzato, S., Cortiula, F., Rossetto, C., Pelizzari, G., Aprile, G., & Macerelli, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413669 · Cited by 17
Trombetta, D., Sparaneo, A., Fabrizio, F. P., & Muscarella, L. A. (2016) · Lung Cancer Management · doi:10.2217/lmt-2016-0006 · Cited by 16
Noncoding RNAs and Liquid Biopsy in Lung Cancer: A Literature Review
Haranguș, A., Berindan‐Neagoe, I., Todea, D. A., Şimon, I., & Șimon, M. (2019) · Diagnostics · doi:10.3390/diagnostics9040216 · Cited by 13
“Qian et al. (2016) reported the highest specificity using the amplification-refractory mutation system (ARMS) [133] and came in support of another meta-analysis of 27 studies conducted by Qiu et al. (2015) which concluded that ARMS had the highest clinical utility and diagnostic accuracy [134].”
BackgroundLiquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System
Nordgård, O., Forthun, R. B., Lapin, M., Grønberg, B. H., Kalland, K., Kopperud, R. K., Thomsen, L. C. V., Tjensvoll, K., Gilje, B., Gjertsen, B. T., et al. (2021) · Cancers · doi:10.3390/cancers13081861 · Cited by 12
Liquid Biopsy for Monitoring EC Patients: Towards Personalized Treatment
Piñeiro-Pérez, R., Abal, M., & Muinelo‐Romay, L. (2022) · Cancers · doi:10.3390/cancers14061405 · Cited by 13
“Currently, liquid biopsy-based tests directed to characterize cell free DNA (cfDNA) are approved as companion diagnostics to select targeted therapies in a reduced number of tumours, such as lung or breast cancer [29,30].”
BackgroundMolecular pathology in real time
Ryška, A. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9607-3 · Cited by 14
“Based on these new data, the diagnostic guidelines have been updated in many countries and molecular testing is nowadays an integral part of the diagnostic procedure implemented in complex diagnostics of NSCLC [63] .”
MethodInfluentialWu, Y., Tong, R., Zhang, Y., Hu, B., Zheng, K., Ding, Z., Peng, F., Gong, Y., Liu, Y., & Lü, Y. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s136823 · Cited by 12
“We sequenced the EGFR gene from tissue and blood using conventional ARMS despite its lower sensitivity, 18 rather than using newer techniques such as ddPCR, 12,19–21 because we wanted to analyze both types of biopsy in the same way to identify whether there are other factors, except technology,…”
Shin, S. H., Cha, S., Lee, H. Y., Shin, S., Kim, Y. J., Park, D., Han, K. Y., Oh, Y. J., Park, W., Ahn, M., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-633 · Cited by 12
“Analyses of ctDNA in plasma are intensively studied in patients with advanced-stage lung cancer to guide and monitor genotype-directed therapies (14,15).”
Chougule, A., & Basak, S. (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_540_17 · Cited by 12
Liao, Y., Chen, Y., Kou, X., Xiao, Y., Ye, J., & Wu, A. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.11.023 · Cited by 11
Pang, C., Ma, H., Qin, J., Wang, S., Wan, C., Yang, T., Shen, Y., & Wang, D. (2019) · Medicine · doi:10.1097/md.0000000000015450 · Cited by 11
“A meta-analysis by Luo et al assessed the diagnostic performance of cfDNA, compared with tissues.([43]) The pooled specificity was 0.”
MethodLi, Y., Zhang, F., Yuan, P., Guo, L., Jianming, Y., & He, J. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13418 · Cited by 16
Lei, J., Huang, Y., Zhong, W., Xiao, D., & Zhou, C. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c00575 · Cited by 11
Wang, X., Gao, Y., Wang, B., Zhang, Z., Liang, C., Feng, H., Guo, Y., Da, J., Mo, M., Zhang, M., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0083-oa · Cited by 10
Shin, D., Shim, H. S., Kim, T. J., Park, H. S., Choi, Y., Kim, W. S., Kim, L., Chang, S. H., Song, J. S., Kim, H. J., et al. (2019) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2019.02.22 · Cited by 10
Leighl, N. B., Kamel‐Reid, S., Cheema, P. K., Laskin, J. J., Karsan, A., Zhang, T., Stockley, T. L., Barnes, T. A., Tudor, R., Liu, G., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00335 · Cited by 10
Imakita, T., Matsumoto, H., Hirano, K., Morisawa, T., Sakurai, A., & Kataoka, Y. (2019) · BMC Cancer · doi:10.1186/s12885-019-5309-x · Cited by 9
“[10] reported the diagnostic accuracy of a particular method of EGFR mutation detection, but patients’ survival rates were not described.”
MethodZhang, H., Hu, Y., Wang, Y., Song, X., Hu, Y., Ma, L., Yang, X., Li, K., Qin, N., Wang, J., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.942123 · Cited by 11
Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC)
Rolfo, C. D., Castiglia, M., Perez, A., Reclusa, P., Pauwels, P., Sober, L., Passiglia, F., & Russo, A. D. (2017) · Current clinical pathology · doi:10.1007/978-3-319-55661-1_12 · Cited by 9
Analytical Validation of an Error-Corrected Ultra-Sensitive Ctdna Next-Generation Sequencing Assay
Fettke, H., Steen, J. A., Kwan, E. M., Bukczynska, P. E., Keerthikumar, S., Goode, D. L., Docanto, M. M., Ng, N., Martelotto, L. G., Hauser, C., et al. (2020) · BioTechniques · doi:10.2144/btn-2020-0045 · Cited by 9
Clinical mutation assay of tumors: new developments
Starostik, P. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000427 · Cited by 9
Liquid biopsy in the management of advanced lung cancer: Implementation and practical aspects
Fernandes, G., Rodrigues, A., Matos, C., Barata, F. J., Cirnes, L., Ferreira, L., Lopes, J. A., Felizardo, M., Fidalgo, P., Brito, U., et al. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100725 · Cited by 7
Park, S., Lee, J.-C., & Choi, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112236 · Cited by 9
“sensitivity of 60% and specificity of 94% for the detection of EGFR mutations in the plasma or serum [45].”
BackgroundDeig, C. R., Mendonca, M. S., & Lautenschlaeger, T. (2017) · Radiation Research · doi:10.1667/rr14613.1 · Cited by 7
Hanibuchi, M., Kanoh, A., Kuramoto, T., Saito, T., Tobiume, M., Saijo, A., Kozai, H., Kondo, M., Morizumi, S., Yoneda, H., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26951 · Cited by 7
“Meta-analysis which comparing paired cfDNA and tissue-based assay results concluded that EGFR mutation detection by cfDNA is of adequate diagnostic accuracy [17].”
MethodMolecular profile of liquid biopsies: next generation biomarkers to improve lung cancer treatment
Bianchi, F. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.598 · Cited by 5
Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients?
Remón, J., Gorham, J., Besse, B., & Sculier, J. (2015) · European Respiratory Journal · doi:10.1183/13993003.01482-2015 · Cited by 5
Billaud, A., Verrièle, V., Dauvé, J., Chevalier, L.-M., & Morel, A. (2020) · Diagnostics · doi:10.3390/diagnostics10080527 · Cited by 6
Intérêts de l’ADN circulant pour la prise en charge du cancer broncho-pulmonaire
Tissot, C., Villar, S., Olivier, M., & Couraud, S. (2015) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2015.05.001 · Cited by 6
Sui, L., Meng, H., Xing, L., Zhang, Y., Wang, J., & Yin, X. (2025) · Meta-Radiology · doi:10.1016/j.metrad.2025.100169 · Cited by 6
Mirtavoos‐Mahyari, H., Ghadami, M., Khosravi, A., Esfahani‐Monfared, Z., Seifi, S., Motevaseli, E., Toutkaboni, M. P., & Modarressi, M. H. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.12.3591 · Cited by 3
“…and specifity were 65.7% and of 99.8%, respectively (Douillard et al., 2014)Two large meta-analyses comprising 20 and 25 studies, respectively (Luo et al., 2014; Kimura et al.,1992). compared the performance of cfDNA and tissue for EGFR mutation detection and demonstrated pooled sensitivity…”
BackgroundInfluentialHaselmann, V., Hedtke, M., & Neumaier, M. (2022) · Journal of Laboratory Medicine · doi:10.1515/labmed-2022-0066 · Cited by 4
The Introduction and Clinical Application of Cell-Free Tumor DNA
Li, J., Liu, R., Huang, C., Chen, S., & Xu, M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7717-8_4 · Cited by 4
Nam, Y., Kim, H. C., Kim, Y., Jang, S. H., Lee, K. Y., Lee, S. Y., Lee, S. H., Lee, S. Y., Yoon, S. H., Ryu, J., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13857 · Cited by 4
Rebuttal from Dr. Mino-Kenudson
Mino-Kenudson, M. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.08.02 · Cited by 4
“In fact, while approximately 30% of small tissue samples are insufficient for molecular testing (2,9), the overall sensitivity of genotyping using cfDNA compared to tissue genotyping is approximately 70–75% (10,11).”
BackgroundClinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma
Incharoen, P., Jinawath, A., Arsa, L., Kamprerasart, K., Trachu, N., Monnamo, N., Khiewngam, K., Muntham, D., Chansriwong, P., Sirachainan, E., et al. (2022) · Cancer Biomarkers · doi:10.3233/cbm-220079 · Cited by 3
Gynecologic Cancer Screening and Prevention: State of the Science and Practice
Tran, C., Diaz-Ayllon, H. P., Abulez, D. S., Chinta, S., Williams‐Brown, M. Y., & Desravines, N. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01301-z · Cited by 4
Quantification of concentration and assessment of EGFR mutation in circulating DNA
Mazurek, A. M., Pierzyna-Świtała, M., Giglok, M., Dworzecka, U., Suwiński, R., & Małusecka, E. (2015) · Cancer Biomarkers · doi:10.3233/cbm-150471 · Cited by 3
Mao, X., Zhang, Y., Xie, F., Zheng, X., & Sun, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20291 · Cited by 3
EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience
Ianza, A., Chicco, A. D., Biagi, C., Giudici, F., Dicorato, A., Guglielmi, A., Variola, F., Tomasi, S., Roviello, G., Generali, D., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03658-8 · Cited by 4
“Two large meta-analysis studies (Qiu et al. 2015; Luo et al. 2015) were conducted to compare cfDNA with tumor tissue in terms of diagnostic accuracy for EGFR mutations.”
MethodJin, J., He, J., Yan, X., Zhao, Y., Zhang, H., Zhuang, K., Wen, Y., & Gao, J. (2022) · PubMed · Cited by 3
Targeting Oncogenic Driver Mutations in Lung Cancer
Lee, M. H., Rous, F. A., Borczuk, A., Liu, S. V., Gadgeel, S. M., & Halmos, B. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009336123 · Cited by 3
Selvarajah, S., Plante, S., Speevak, M. D., Vaags, A. K., Hamelinck, D., Butcher, M. K., McCready, M. E., Grafodatskaya, D., Blais, N., Tran‐Thanh, D., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100212 · Cited by 3
Leprieur, E. G., Cortot, A. B., Cadranel, J. L., & Wislez, M. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.06.007 · Cited by 3
“Comme pour la détection des mutations sensibilisatrices d’EGFR [21-24], l’utilisation de l’ADN tumoral circulant pour la détection de la mutation T790M est intéressante: utilisation facile, possiblement répétée, et reflétant l’hétérogénéité tumorale.”
Liquid biopsy for T790M mutation detection: A ray of hope?
Mohan, A., & Mittal, S. (2019) · Lung India · doi:10.4103/lungindia.lungindia_543_19 · Cited by 3
“Five systematic reviews/meta-analyses have been conducted to determine the consistency and diagnostic ability of serum/plasma for detecting EGFR mutations.[6-10] The results of these show that blood may be a promising alternative to tissue for detecting EGFR mutations in NSCLC, especially after disease progression on…”
BackgroundKakouri, A. C., Spiliotaki, M., Deltas, C. C., Papagregoriou, G., & Charalambous, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125518 · Cited by 2
“Accordingly, supplementary tissue biopsies are used when feasible for comprehensive molecular profiling [12–14].”
Ginghină, O., & Niţipir, C. (2018) · InTech eBooks · doi:10.5772/intechopen.72701 · Cited by 2
“Cell-free DNA (cfDNA) is a powerful tool for its potential use in a wide range of clinical fields such as cancer research [64, 65], non-invasive prenatal testing [66] and transplant rejection diagnostics [67].”
MethodClinical and Investigational Applications of Liquid Biopsy in Non-Small Cell Lung Cancer
Pérez-Callejo, D., Torrente, M., Romero, A., & Provencio, M. (2016) · Journal of Tumor · doi:10.17554/j.issn.1819-6187.2016.04.95 · Cited by 2
Is the determination of ctDNA a scientific “spy” that foresees cancer?
de Macedo, J. E., & Machado, M. (2017) · World Journal of Respirology · doi:10.5320/wjr.v7.i2.35 · Cited by 2
Zhou, J., Li, Y., Zhang, Y., Dai, H., & Guo, S. (2021) · Future Oncology · doi:10.2217/fon-2021-0064 · Cited by 2
Chen, C., Douglas, M. P., Ragavan, M. V., Phillips, K. A., & Jansen, J. P. (2023) · medRxiv · doi:10.1101/2023.10.27.23297657 · Cited by 2
“In contrast to previous systematic literature reviews/meta-analyses on ctDNA detection of EGFR or KRAS 18,22,23,25,26 , we assessed the diagnostic accuracy of ctDNA for detecting multiple driver mutations simultaneously rather than focusing on single mutation thereby providing more relevant…”
BackgroundMethodResultAttitudes of patients and physicians on repeat biopsies for lung cancer
Chia, P. L., Devitt, B. A., Clay, T. D., McLachlan, S., Mitchell, P. L. R., & John, T. (2017) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2017.1339557 · Cited by 1
Brooks, H., Li, L., Addeo, A., Stevens, M., Comins, C., & Oltean, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1197037 · Cited by 1
Kokori, E., Olatunji, G. D., Ogieuhi, I. J., Muogbo, I., Isarinade, D. T., Ukoaka, B. M., Ajayi, I., Ezenwoba, C., Samuel, O., Nurudeen-Busari, H., et al. (2024) · Medicine · doi:10.1097/md.0000000000037154 · Cited by 1
“[19] These analytes harbor critical information concerning the presence and characteristics of cancer.”
BackgroundThe molecular approach to diagnosis in lung cancer
Moore, D. A., & Quesne, J. P. C. L. (2015) · British Journal of Hospital Medicine · doi:10.12968/hmed.2015.76.5.c74 · Cited by 1
Castro-Valencia, K., González-Herrera, L. J., Muñoz-Santos, E., López-González, P., Sosa–Escalante, J. E., Pérez‐Mendoza, G., & Medina‐Escobedo, G. (2018) · REVISTA BIOMÉDICA · doi:10.32776/revbiomed.v29i3.622
“Así mismo, un metaanálisis ha evidenciado que la sangre es un sustituto del tejido tumoral para detectar mutaciones en EGFR (13).”
Background„Liquid biopsy“ – Einsatzmöglichkeiten in der molekularen Tumordiagnostik
Stögbauer, F., Weichert, W., & Pfarr, N. (2019) · Der Onkologe · doi:10.1007/s00761-019-00684-7 · Cited by 1
Cho, Y. G., Park, J., Han, J. Y., & Kim, T. Y. (2023) · Genes · doi:10.3390/genes14061219 · Cited by 1
“4–68% for cfDNA, when plasma samples were tested to determine the EGFR mutational status compared with matched tumor tissues [23,25].”
BackgroundMethodHeredia, D., Bolaño-Guerra, L., Valencia-Velarde, A., Varela‐Santoyo, E., Lara‐Mejía, L., Cárdenas-Fernández, D., Orozco, M., Cruz‐Rico, G., & Arrieta, O. G. (2023) · Cancer Biomarkers · doi:10.3233/cbm-230124 · Cited by 2
Use of Diagnostic Tests in Advanced Non–Small Cell Lung Cancer
Eaby‐Sandy, B. (2017) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2017.8.2.5 · Cited by 1
“%) and a specificity of 95.9% (95% CI: 92.9%–97.7%), respectively (Luo, Shen, & Zheng, 2014; Qiu et al., 2015).”
InfluentialCritical points in the management of EGFR-mutated non-small cell lung cancer
Casaluce, F., & Gridelli, C. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-269 · Cited by 1
“As reported by Luo (19), the Achilles heel for the detection of EGFR mutations on ctDNA is lower sensitivity (67.”
BackgroundInfluentialPeng, M., Xie, Y., Li, X., Qian, Y., Tu, X., Yao, X., Cheng, F., Xu, F., Kong, D., He, B., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/453803 · Cited by 1
“Another meta-analysis has also put the pooled sensitivity in the range of 60%’s (22).”
BackgroundPerspective of a pulmonologist: what might we expect and what do we need to know?
Guibert, N. M., Noël‐Savina, E., & Mazières, J. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.10011014
Refined Glioma Classification based on Molecular Pathology
Mizoguchi, M. (2015) · Japanese Journal of Neurosurgery · doi:10.7887/jcns.24.366
Clinical Lung Cancer Mutation Detection
Jahn, S. C., & Starostik, P. (2017) · InTech eBooks · doi:10.5772/67168
“Circulating tumor cells were detected in 78% of small‐cell lung cancer patients [46], and both circulating DNA [47] and tumor cells [48] have been successfully used to screen for EGFR mutations in lung cancer.”
BackgroundDas, S., & Horn, L. (2017) · Lung Cancer Management · doi:10.2217/lmt-2016-0019
Tjon‐Kon‐Fat, L. (2018) · DiVA (Digitala Vetenskapliga Arkivet)
Cell-Free DNA Utility and Value of Recommendation
Levy, B. P. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0064-ed
Laisvos DNR reikšmė diagnozuojant plaučių vėžį
Serapinas, D., Medvedeva, A., Čepaitė, J., & Mickevičiūtė, G. (2016) · Pulmonology and allergology · doi:10.37499/pia.274
Liquid Biopsy: A New, Non-Invasive Early Diagnostic and Prognostic Tool in Oncology
Comparetto, C., & Borruto, F. (2020) · Journal of cancer research updates · doi:10.30683/1929-2279.2020.09.06 · Cited by 1
“It is in this sense that the meaning of LB, whose main use at the moment is linked to the analysis of mutations of EGFR gene in patients with NSCLC in an advanced stage, must be explained [63-76].”
Background
Metadata
- Authors
- Luo, J., Shen, L., & Zheng, D.
- Affiliations
- Tongji University (CN)
- Corresponding author
- Zheng, Di
- Venue
- Scientific Reports
- Published
- 2014-09-09
- Volume
- 4
- Issue
- 1
- Pages
- 6269-6269
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5385820
- OpenAlex
- W1979671400
- Cited by
- 212
- References
- 55
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 6 · 2023: 15 · 2022: 10 · 2021: 16 · 2020: 16 · 2019: 21 · 2018: 33 · 2017: 40 · 2016: 25 · 2015: 20
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- cell-free DNA, EGFR mutation, non-small cell lung cancer, liquid biopsy, diagnostic accuracy, EGFR tyrosine kinase inhibitors, tumor markers
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, DNA, Female, Humans, Lung Neoplasms, Male, Mutation, Quinazolines, ROC Curve, Biomarkers, Tumor, Area Under Curve, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.